Effects of the Japanese Encephalitis Virus Genotype V-Derived Sub-Viral Particles on the Immunogenicity of the Vaccine Characterized by a Novel Virus-Like Particle-Based Assay

Vaccines
Sarah HonjoTomohiro Ishikawa

Abstract

Japanese encephalitis virus (JEV) is classified into five genotypes labelled I through V. Although the genotype V (GV) JEV was originally found and had apparently been limited in Malaysia for more than 50 years, its emergence in Korea and China has recently been reported. Therefore, the GV JEV might be spreading over new geographical regions as a cause of potential public health problems. However, it is unknown whether the currently available JEV vaccines are effective against the emerging GV strains. To investigate this issue, a novel virus-like particle-based neutralizing assay was developed in this study. By using this assay, the inactivated JEV vaccine used in Japan and the recombinant sub-viral particles (SVPs) bearing the E protein of the GV Muar strain were characterized for the immunogenicity against the GV JEV. Although the inactivated vaccine alone failed to elicit a detectable level of neutralizing antibodies against the GV JEV, the vaccine added with the Muar-derived SVPs induced relatively high titers of neutralizing antibodies, associated with the efficient Th1 immune responses, against the GV JEV. The results indicate that addition of the GV JEV-derived antigens may be useful for developing the vaccine that is un...Continue Reading

References

Jan 1, 1987·The Journal of Experimental Medicine·J P CoutelierJ Van Snick
Mar 23, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·T SolomonV T Khanh
Feb 14, 2003·Journal of Virology·Tom SolomonAlan D T Barrett
Nov 17, 2007·Cell Host & Microbe·Theodore C PiersonMichael S Diamond
Apr 5, 2008·European Journal of Immunology·Vania ManolovaMartin F Bachmann
Dec 11, 2008·Annual Review of Entomology·Andrew F van den HurkJohn S Mackenzie
Mar 1, 2011·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Manal A F MohammedTom Solomon
Jul 14, 2011·PLoS Neglected Tropical Diseases·Ming-Hua LiGuo-Dong Liang
Sep 29, 2011·Virology Journal·Ratree TakhampunyaBrian P Evans
Oct 18, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elina O ErraAnu Kantele
Apr 11, 2013·International Reviews of Immunology·Etsushi KurodaKen J Ishii
Jun 11, 2014·The Journal of General Virology·Hsin-Wei ChenChien-Hsiung Pan
Jan 1, 2014·Vaccines·Benoît LevastSylvia van Drunen Littel-van den Hurk
Aug 11, 2017·Journal of Virology·Himanshu GargAnjali Joshi

❮ Previous
Next ❯

Methods Mentioned

BETA
in vitro transcription
electrophoresis
Assay
ELISA

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.